Malaria in Pregnancy: Severe Risks Uncovered

World Malaria Day, observed annually on April 25, underscores the critical need for malaria prevention and treatment. Malaria, a mosquito-borne parasitic disease, poses significant threats, with an estimated 282 million cases and 610,000 deaths globally in 2024, disproportionately affecting the African region.

For pregnant women, malaria presents amplified risks, potentially causing severe maternal anemia, low birth weight, preterm birth, miscarriage, and even stillbirth. The parasite's impact on the placenta can restrict nutrient and oxygen flow to the fetus, hindering development. In severe cases, congenital malaria can occur, where the infant is born with the infection.

Preventing malaria in pregnant individuals involves dual strategies: rigorous mosquito avoidance and preventive drug therapy. Staying in screened areas, using treated mosquito nets, and applying repellents help minimize exposure, especially during dusk and dawn. Intermittent Preventive Treatment in Pregnancy (IPTp) is administered to provide protection regardless of symptoms.

Prompt and effective treatment is vital for pregnant women diagnosed with malaria to rapidly clear the parasite. While treatment options exist, including artemether-lumefantrine for resistant strains, pregnant women are more susceptible to severe complications. These can include hypoglycemia and pulmonary edema, with maternal mortality rates potentially reaching 50% if untreated.